Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06184126 · ClinicalTrials.gov registry record · NA

Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises

A NA study of Sickle Cell Disease and Acute Pain, sponsored by University of Maryland, Baltimore.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06184126 is a NA study of Sickle Cell Disease and Acute Pain that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 30 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06184126, a NA study of Sickle Cell Disease and Acute Pain, is actively recruiting participants, sponsored by University of Maryland, Baltimore.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This study aims to evaluate the use of virtual reality as an adjunct to standard care for patients with sickle cell disease experiencing vaso-occlusive crises.

Interventions

  • DEVICE Virtual Reality Headset and Hand-Held Controllers
  • OTHER Blindfolding and Noise Cancelling

Study Locations (1)

Maryland

  • University of Maryland Medical Systems - Baltimore

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-11-01
Est. Completion 2026-12-31
Phase NA

Sponsor

University of Maryland, Baltimore

560 total trials

What the Registry Record Tells You About NCT06184126

The ClinicalTrials.gov registry entry for NCT06184126 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (90% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Virtual Reality Headset and Hand-Held Controllers is the first listed.

NCT06184126 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT06184126 about?

NCT06184126 is a clinical study titled "Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises". This study aims to evaluate the use of virtual reality as an adjunct to standard care for patients with sickle cell disease experiencing vaso-occlusive crises.

What is the current status of trial NCT06184126?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-11-01. Estimated completion is 2026-12-31.

What conditions does trial NCT06184126 study?

This clinical trial studies the following conditions: Sickle Cell Disease, Acute Pain, Vaso-Occlusive Pain Episode in Sickle Cell Disease.

What interventions are being tested in trial NCT06184126?

The interventions under investigation include: Virtual Reality Headset and Hand-Held Controllers (DEVICE), Blindfolding and Noise Cancelling (OTHER).

Who is sponsoring clinical trial NCT06184126?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06184126 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.